Our Science

Istari Oncology is developing novel immunotherapies for cancer treatment based on technology developed at Duke University. Our science is focused on two platforms that are in clinical development, Polio Virus Sabin-Rhinovirus Poliovirus (PVSRIPO) and Antibody-Directed Immuno-Conjugates (ADC).

Duke University licensed a broad range of patents and patent applications to Istari in 2016 and provided access to additional intellectual property created at Duke to continue clinical and commercial development of these technologies.